A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
出版年份 2013 全文链接
标题
A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations
作者
关键词
HIV-1, Maraviroc, Resistance, Env, gp120, V3 loop, CCR5 N-terminus, CCR5 ECLs
出版物
Retrovirology
Volume 10, Issue 1, Pages 43
出版商
Springer Nature
发表日期
2013-04-20
DOI
10.1186/1742-4690-10-43
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Differential Use of CCR5 by HIV-1 Clinical Isolates Resistant to Small-Molecule CCR5 Antagonists
- (2012) Timothy J. Henrich et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Macrophage-tropic HIV-1 variants from brain demonstrate alterations in the way gp120 engages both CD4 and CCR5
- (2012) Hamid Salimi et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Enhanced Recognition and Neutralization of HIV-1 by Antibody-Derived CCR5-Mimetic Peptide Variants
- (2012) J. J. Chiang et al. JOURNAL OF VIROLOGY
- V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc
- (2012) Reem Berro et al. VIROLOGY
- Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance
- (2012) Cleo G. Anastassopoulou et al. VIROLOGY
- Affinofile profiling: How efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV
- (2012) Kelechi Chikere et al. VIROLOGY
- Tyrosine Sulfation Influences the Chemokine Binding Selectivity of Peptides Derived from Chemokine Receptor CCR3
- (2011) John Z. Zhu et al. BIOCHEMISTRY
- Divergent and Site-Selective Solid-Phase Synthesis of Sulfopeptides
- (2011) Deni Taleski et al. Chemistry-An Asian Journal
- Mapping and Characterization of Vicriviroc Resistance Mutations From HIV-1 Isolated from Treatment-Experienced Subjects Enrolled in a Phase II Study (VICTOR-E1)
- (2011) Paul M McNicholas et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- A Tyrosine-Sulfated CCR5-Mimetic Peptide Promotes Conformational Transitions in the HIV-1 Envelope Glycoprotein
- (2011) J. A. Kwong et al. JOURNAL OF VIROLOGY
- HIV-1 Escape from the CCR5 Antagonist Maraviroc Associated with an Altered and Less-Efficient Mechanism of gp120-CCR5 Engagement That Attenuates Macrophage Tropism
- (2011) M. Roche et al. JOURNAL OF VIROLOGY
- Alternative Coreceptor Requirements for Efficient CCR5- and CXCR4-Mediated HIV-1 Entry into Macrophages
- (2011) K. Cashin et al. JOURNAL OF VIROLOGY
- HIV-1 Clinical Isolates Resistant to CCR5 Antagonists Exhibit Delayed Entry Kinetics That Are Corrected in the Presence of Drug
- (2011) O. Putcharoen et al. JOURNAL OF VIROLOGY
- HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry
- (2011) Michael Roche et al. Retrovirology
- CD4-binding site alterations in CCR5-using HIV-1 envelopes influencing gp120–CD4 interactions and fusogenicity
- (2011) Jasminka Sterjovski et al. VIROLOGY
- Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41
- (2011) Cleo G. Anastassopoulou et al. VIROLOGY
- Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc
- (2010) Pierre Delobel et al. AIDS
- HIV Type 1 from a Patient with Baseline Resistance to CCR5 Antagonists Uses Drug-Bound Receptor for Entry
- (2010) John C. Tilton et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Evolution of CCR5 Antagonist Resistance in an HIV-1 Subtype C Clinical Isolate
- (2010) Timothy J Henrich et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Maraviroc versus Efavirenz, Both in Combination with Zidovudine‐Lamivudine, for the Treatment of Antiretroviral‐Naive Subjects with CCR5‐Tropic HIV‐1 Infection
- (2010) David A. Cooper et al. JOURNAL OF INFECTIOUS DISEASES
- Characterization of Emergent HIV Resistance in Treatment‐Naive Subjects Enrolled in a Vicriviroc Phase 2 Trial
- (2010) Paul McNicholas et al. JOURNAL OF INFECTIOUS DISEASES
- A Maraviroc-Resistant HIV-1 with Narrow Cross-Resistance to Other CCR5 Antagonists Depends on both N-Terminal and Extracellular Loop Domains of Drug-Bound CCR5
- (2010) John C. Tilton et al. JOURNAL OF VIROLOGY
- HIV-1 Resistance to CCR5 Antagonists Associated with Highly Efficient Use of CCR5 and Altered Tropism on Primary CD4+ T Cells
- (2010) J. M. Pfaff et al. JOURNAL OF VIROLOGY
- Clinical resistance to vicriviroc through adaptive V3 loop mutations in HIV-1 subtype D gp120 that alter interactions with the N-terminus and ECL2 of CCR5
- (2010) Robert A. Ogert et al. VIROLOGY
- An altered and more efficient mechanism of CCR5 engagement contributes to macrophage tropism of CCR5-using HIV-1 envelopes
- (2010) Jasminka Sterjovski et al. VIROLOGY
- Coreceptors and HIV-1 Pathogenesis
- (2010) Paul R. Gorry et al. Current HIV/AIDS Reports
- Regulation of Chemokine Recognition by Site-Specific Tyrosine Sulfation of Receptor Peptides
- (2009) Levi S. Simpson et al. CHEMISTRY & BIOLOGY
- Tissue-Specific Sequence Alterations in the Human Immunodeficiency Virus Type 1 Envelope Favoring CCR5 Usage Contribute to Persistence of Dual-Tropic Virus in the Brain
- (2009) L. Gray et al. JOURNAL OF VIROLOGY
- Structure-Function Analysis of Human Immunodeficiency Virus Type 1 gp120 Amino Acid Mutations Associated with Resistance to the CCR5 Coreceptor Antagonist Vicriviroc
- (2009) R. A. Ogert et al. JOURNAL OF VIROLOGY
- A Quantitative Affinity-Profiling System That Reveals Distinct CD4/CCR5 Usage Patterns among Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Strains
- (2009) Samantha. H. Johnston et al. JOURNAL OF VIROLOGY
- Quantitative Deep Sequencing Reveals Dynamic HIV-1 Escape and Large Population Shifts during CCR5 Antagonist Therapy In Vivo
- (2009) Athe M. N. Tsibris et al. PLoS One
- Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
- (2009) C. G. Anastassopoulou et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inefficient entry of vicriviroc-resistant HIV-1 via the inhibitor-CCR5 complex at low cell surface CCR5 densities
- (2009) Pavel Pugach et al. VIROLOGY
- Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
- (2009) Reem Berro et al. PLoS Pathogens
- Virologic Failure in First-Line Human Immunodeficiency Virus Therapy with a CCR5 Entry Inhibitor, Aplaviroc, plus a Fixed-Dose Combination of Lamivudine-Zidovudine: Nucleoside Reverse Transcriptase Inhibitor Resistance Regardless of Envelope Tropism
- (2008) J. F. Demarest et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Virologic Failure in Therapy-Naive Subjects on Aplaviroc plus Lopinavir-Ritonavir: Detection of Aplaviroc Resistance Requires Clonal Analysis of Envelope
- (2008) K. M. Kitrinos et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Phase II Study of Vicriviroc versus Efavirenz (both with Zidovudine/Lamivudine) in Treatment‐Naive Subjects with HIV‐1 Infection
- (2008) Raphael J. Landovitz et al. JOURNAL OF INFECTIOUS DISEASES
- In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected Subject
- (2008) A. M. N. Tsibris et al. JOURNAL OF VIROLOGY
- Subgroup Analyses of Maraviroc in Previously Treated R5 HIV-1 Infection
- (2008) Gerd Fätkenheuer et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started